Tourette Syndrome

Potential First-in-Class Treatment for Tourette Syndrome Gets Fast Track Status

The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS). Unlike other TS treatments, which act on dopamine D2 receptors, ecopipam works by selectively blocking the actions of the D1 receptor. This mechanism may potentially reduce the likelihood of metabolic…